Clinical Trials on Multiple Chronic Conditions

Total 434177 results

Biogen

Completed

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis (EXPLORE)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (OBSERVE)

Relapsing-Remitting Multiple Sclerosis

Poland, Hungary, United States, Czech Republic
Genzyme, a Sanofi Company

Terminated

Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

Relapsing-remitting Multiple Sclerosis

Russian Federation, United States, Canada, Poland
Merck KGaA, Darmstadt, Germany

Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR)

Relapsing-Remitting Multiple Sclerosis

Germany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
Merck Sharp & Dohme LLC

Terminated

A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)

Relapsing-Remitting Multiple Sclerosis
Biogen

Terminated

Natalizumab (Tysabri) Re-Initiation of Dosing (STRATA)

Relapsing-Remitting Multiple Sclerosis

Finland, Germany, Spain, Belgium, Italy, Canada, France, New Zealand, Israel, Hungary, Greece, Australia, Netherlands, United Kingdom, Denmark, Ireland, Sweden, Poland, Czech Republic, Switzerland, Turkey
Biogen
AbbVie

Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Genzyme, a Sanofi Company

Completed

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (EMERALD)

Relapsing-remitting Multiple Sclerosis

Belgium, Spain, France, Netherlands
PD Dr. Marcus Müller
BfARM, Bonn; DZNE, Bonn

Unknown

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RESI)

Relapsing-remitting Multiple Sclerosis

Germany
Nantes University Hospital

Completed

Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

France
Biogen

Terminated

Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting | Relapsing-Remitting Multiple Sclerosis

Canada
Biogen

Completed

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Japan
University of Missouri, Kansas City

Completed

Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS (MIMS)

Relapsing-remitting Multiple Sclerosis

United States
University of Missouri, Kansas City
National Multiple Sclerosis Society

Completed

Development of a Motivational Intervention to Improve Treatment Adherence in MS (MIMS)

Relapsing-remitting Multiple Sclerosis

United States
Biogen

Withdrawn

Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate (TECNERGY)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (REFINE)

Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Germany, Belgium
Biogen

Completed

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (DEFINE)

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Czech Republic, France, Italy, Mexico, South Africa, United Kingdom, Germany, Poland, Romania, Ukraine, Netherlands, Austria, Canada, Israel, New Zealand, Slovakia, Greece, Serbia, India, Belgium, Switzerland, ... and more
Waukesha Memorial Hospital
The Cleveland Clinic

Completed

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis

Russian Federation
Merck KGaA, Darmstadt, Germany

Completed

A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) (TOURIMS)

Relapsing-Remitting Multiple Sclerosis
Opexa Therapeutics, Inc.

Completed

Autologous T Cell Vaccine (TCV) for Multiple Sclerosis (TERMS)

Relapsing-Remitting Multiple Sclerosis

United States
Neurognostics

Terminated

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Marshall University
Edwards Foundation, Inc.

Terminated

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

Chronic Lymphocytic Leukemia | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

United States
George Washington University

Recruiting

PVB vs Ketamine/Lidocaine in Rib Fracture Patients

Pain, Acute | Rib Fractures | Rib Fracture Multiple | Rib Trauma

United States
M.D. Anderson Cancer Center
Eligix

Terminated

CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

Multiple Myeloma | Chronic Lymphocytic Leukemia | Chronic Myelogenous Leukemia | Non Hodgkin's Lymphoma | Hodgkin's Disease

United States
US Department of Veterans Affairs

Completed

Health Behavior Change in Chronic Disease Management

Multiple Sclerosis

United States
Texas Tech University
National Center for Complementary and Integrative Health (NCCIH)

Completed

Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention

Multiple Drug Use

United States
Han weidong

Unknown

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Malignancies Multiple

China
Bristol-Myers Squibb

Recruiting

A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants (AppreZiate)

Relapsing-remitting Multiple Sclerosis (RRMS)

Spain
Hoffmann-La Roche
PPD

Recruiting

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis (Operetta 2)

Relapsing-Remitting Multiple Sclerosis

United States, Belgium, Canada, Spain, India, Italy, Mexico, Portugal, Austria, Brazil, United Kingdom, Germany, Netherlands, Serbia, Argentina, Australia, Bulgaria, France, Greece, Hungary, Poland, Ukraine, Estonia, Denmark, Croatia, Latvia and more
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Polpharma Biologics S.A.

Completed

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® (Antelope)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Belarus, Ukraine, Georgia, Croatia, Moldova, Republic of, Poland, Serbia
Cinnagen

Completed

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis (RRMS)

Iran, Islamic Republic of
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

Relapsing-Remitting Multiple Sclerosis

United States
Germans Trias i Pujol Hospital
Ministerio de Sanidad, Servicios Sociales e Igualdad

Completed

Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis (RRMS)

Spain
Novartis Pharmaceuticals

Terminated

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (TOFIINGO)

Relapsing Remitting Multiple Sclerosis (RRMS)

Germany, Spain, Australia, Israel, Switzerland, Italy, Austria, Greece, Hungary, Czech Republic, Finland
Merck KGaA, Darmstadt, Germany
Smerud Medical Research International AS; Merck Serono Norway

Completed

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects (SCANSMART)

Relapsing Remitting Multiple Sclerosis (RRMS)

Norway
Nationwide Children's Hospital
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS (GRACE-2)

Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome

United States
University of Alabama at Birmingham

Recruiting

Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.

Multiple Sclerosis | Healthy | Fibromyalgia | Chronic Fatigue Syndrome

United States
University of Leicester
Zimmer Biomet; British Heart Foundation; National Health Service, United Kingdom

Withdrawn

Red Cell Rejuvenation for the Attenuation of Transfusion Associated Organ Injury in Cardiac Surgery

Sepsis | Inflammation | Organ Failure, Multiple

United Kingdom
Taipei Medical University WanFang Hospital

Withdrawn

Comparing the Prognosis of Lactate-directed and Goal-directed Therapy in Hyperthermic Intraperitoneal Chemotherapy.

Organ Failure, Multiple
Brno University Hospital

Recruiting

Mortality in Paediatric Intensive Care (Paedmort)

Morbidity, Multiple

Czechia
W.L.Gore & Associates

Active, not recruiting

Global Registry for Endovascular Aortic Treatment (GREAT) (GREAT)

Multiple Pathologies

Australia, Italy, United States, Brazil
Cairo University
Riyadh Fertility and Reproductive Health center

Completed

Fetal Reduction: Mechanical vs Chemical

Multiple Pregnancy

Egypt
EMD Serono

Withdrawn

Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects

Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

Clinical Disease Activity With Long Term Natalizumab Treatment

Relapsing-Remitting Multiple Sclerosis

Czechia, Belgium

Clinical Trials on Multiple Chronic Conditions

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations